Beyond the mutation: integrating radiogenomics, epigenetics, and immune signatures to overcome therapeutic resistance in CNS tumors: a narrative review
The urgent need to develop specific, biomarker-informed approaches that would aim to improve outcomes in this domain of neuro-oncology is highlighted, with emphasis on the role of the tumor microenvironment, low mutational burden, and immune exclusion.